2TAKAHASHI Y, KUSUMI I, ISHIKANE T, et al. In vivo occupation of dopamine DI ,D2 and serotonin 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain[J].Neural Transm, 1998,105(2-3) : 181-191.
3OHNO Y. Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent[J]. Nippon Yakurigaku Zasshi ,2000,116(4) :225-231.
4SHIWA T,AMANO T, MATSUBAYASHI H, et al. Perospirone,a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HTIA receptor[J]. Pharmacol Sci ,2003,93 ( 1 ) : 114-117.
5IWAKAWA M, TERAO T,SOYA A, et al. A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergie effects in human brain: findings from neuroendocrine challenge tests[J].Psychopharmacology, 2004,176 (3 -4 ) : 407-411.
6KAZUTOYO I, SHIN I, AKINORI U, et al. Phase I study of perospirone HCL (SM-9018)[J]. Clinical Report,1997,31 (6):188.
7YASUI-FURUKORI N, FURUKORI H, NAKAGAMI T, et al.Steady-state pharmacokinetics of a new antipsychotic agent perospirnoe and its active metabolite, and its relationship with prolactin response[J]. Ther Drug Monit, 2004,26(4):361-365.
8KITAMURA A, MIZUNO Y, NATSUI K, et al. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone[J]. Biopharm Drug Dispos, 2005,26 (2) :59-65.
9SHIMAKURA J, TANI N, MIZUNO Y, et al. In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes[J]. Eur J Drug Metab Pharmacokinet ,2003,28( 1 ) :67-72.
10ONRUST SV, McCLELLAN K. Perospirone[J]. CNS Drugs,2001,15(4) :329-337.
4Suzuki Y, Sawamura K, Ono S, et al. The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients [ J ]. Prog Neuropsychopharmac01 Biol Psychiatry, 2010, 34 (6): 830-833.
5Takekita Y, Kato M, Wakeno M, et al. A 12 - week randomized, open - label study of perospirone versus aripiprazole in the treatment of Japaneses chizophrenia patients [ J ]. Prog Neuropsychopharmacol Biol Psychiatry, 2013, 40: 110-114.
6Takahashi S, Suzuki M, Uchiyama M. A case of schizophrenia with meige syndrome induced by perospirone successfully treated with biperiden [ J ]. J Neuropsychiatry Clin Neurosci, 2013, 25 (1): E28.
7Tsujino N, Nemoto T, Morita K, et al. Long - term Efficacy and Tolerability of Perospirone for Young Help - seeking People at Clinical High Risk: a Preliminary Open Trial [ J ]. Clin Psychopharmacol Neurosci, 2013, 11 (3): 132-136.
8Arakawa R, Ito H, Takano A, et al. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects [J]. Psychophannacology (Berl) , 2010, 209 (4) : 285 -290.
9Suzuki H, Gen K, Inoue Y. An unblinded comparison of the clinical and cognitive effects of switctfing from first - generation antipsyehotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia [ J ]. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35 (1): 161-168.
10Takekita Y, Fabbri C, Kato M, et al. HTR1A Gene Polymorphisms and 5 - HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia [ J ]. J Clin Psychopharmacol, 2015, 35 (3): 220-227.
